Posted by Michael Wonder on 20 Jul 2023
Ipsen announces European Commission decision on palovarotene for the treatment of FOP
19 July 2023 - European Commission determines not to grant marketing authorisation approval for palovarotene for fibrodysplasia ossificans progressiva.
Ipsen announced today that the European Commission has followed guidance provided by the CHMP in May this year, and has not granted marketing authorisation for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva.
